In a recent study published in JAMA Network Open, researchers from the University of Michigan have uncovered a concerning link between commonly prescribed hospice medications and an increased risk of mortality among patients with dementia. With the rising numbers of Americans diagnosed with dementia, understanding the implications of medication use in hospice care has never been more critical.
Understanding Hospice Care and Its Challenges
Hospice care is designed to provide comfort and dignity to patients at the end of life. However, for many patients living with dementia, the course of the illness can be long and unpredictable. This variability necessitates careful consideration of treatment options to ensure they align with patients' goals and stages of illness.
Key Findings of the Study
The study analyzed data from over 139,000 nursing home residents with Alzheimer's disease or related dementias who were enrolled in hospice between 2014 and 2018. The findings indicated that patients beginning treatment with benzodiazepines or antipsychotics after hospice enrollment faced:
| Medication Type | Increased Risk of Death within 6 Months |
|---|---|
| Benzodiazepines | 41% |
| Antipsychotics | 16% |
Notably, nearly half of the patients (48%) received a benzodiazepine prescription, while 13% were prescribed an antipsychotic soon after enrollment—even though none had received these medications in the six months prior to entering hospice care. The average duration of hospice stay for these patients was over 130 days, indicating that many were not necessarily in their final phase of life.
The Risks Associated with Medications
While medications like benzodiazepines and antipsychotics can potentially provide relief from distressing symptoms such as agitation and anxiety, they also entail significant risks. Common adverse effects in older adults include:
- Confusion
- Sedation
- Increased risk of falls
The U.S. Food and Drug Administration (FDA) has issued boxed warnings regarding the increased risk of mortality associated with antipsychotics in patients with dementia and has raised similar concerns regarding benzodiazepines.
Policies and Gaps in Care
The study highlights notable gaps in hospice policies concerning medication management for patients with dementia:
| Issue | Description |
|---|---|
| Lack of Oversight | Medications used in hospice care are not consistently reported or monitored by Medicare, leading to potential safety issues. |
| Inadequate Acknowledgment of Disease Progression | The six-month Medicare hospice eligibility period often does not align with the prolonged and uncertain course of dementia. |
The Need for Specialized Guidance
As more than 60% of individuals with dementia are now entering hospice, the importance of developing dementia-specific hospice quality measures and prescribing guidelines is underscored by these findings. Lauren B. Gerlach, DO, MS, the lead author of the study, emphasizes that there is a need for better transparency in prescribing data, which may support hospice clinicians in making more evidence-informed decisions.
This need for improved oversight is critical, considering that previous research demonstrated significant variations in prescribing patterns across hospice agencies. These discrepancies may indicate a reliance on agency culture or policies rather than patient-centered care.
Conclusion and Future Directions
In light of these findings, it is essential to reconsider how medications for patients with dementia are managed in hospice settings. Developing care models and prescribing guidelines that reflect the unique trajectory of dementia can potentially enhance the quality of life and overall outcomes for these patients. As the study suggests, maintaining communication with patients and families at this critical juncture is paramount in ensuring that care not only prolongs life but also preserves dignity and quality of life.
More information can be found here.
Discussion